本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Kiniksa Pharmaceuticals Ltd.

35.48
+1.203.50%
盘后35.500.0200+0.06%19:05 EDT
成交量:60.04万
成交额:2,102.81万
市值:26.29亿
市盈率:537.28
高:35.53
开:34.40
低:34.00
收:34.28
52周最高:35.53
52周最低:17.82
股本:7,410.77万
流通股本:3,355.22万
量比:1.47
换手率:1.79%
股息:- -
股息率:- -
每股收益(TTM):0.0660
每股收益(LYR):-0.6047
净资产收益率:1.03%
总资产收益率:0.46%
市净率:5.31
市盈率(LYR):-58.67

数据加载中...

2024/10/29

重要事件披露

Form 8-K - Current report
2024/10/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/08

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/10/08

重要事件披露

Form 8-K - Current report
2024/09/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

摘牌通告

Form 15-15D/A - Suspension of duty to report [Section 13 and 15(d)]: [Amend]
2024/07/23

重要事件披露

Form 8-K - Current report
2024/07/02

SEC问询函

Form CORRESP - Correspondence
2024/06/28

摘牌通告

Form 15-15D - Suspension of duty to report [Section 13 and 15(d)]
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments